• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Statins associated with improvement of rare lung disease
This study suggests that oral statin therapy may be a new approach for patients with autoimmune pulmonary alveolar proteinosis.AUTHORSThe study ’s co-senior authors are Dr. Elizabeth Tarling of UCLA and Dr. Bruce Trapnell of Children’s Hospital Medical Center of Cincinnati, Ohio. Other authors are listed in the journal article.JOURNALThe study was  published in the journal Nature Communications. FUNDINGThe National Institutes of Health funded the research.Learn more about the  cardiovascular research theme at UCLA. 
Source: UCLA Newsroom: Health Sciences - August 17, 2018 Category: Universities & Medical Training Source Type: news